** Shares of drugmaker Eli Lilly LLY.N fall 4.3% to $860.72 premarket
** Q1 sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates
** Zepbound posted Q1 sales of $2.31 billion compared with analysts' average estimate of $2.33 billion, as per data compiled by LSEG
** Co also cuts annual adj. profit forecast to between $20.78 and $22.28 per share from $22.50 and $24 previously
** Sales of diabetes drug Mounjaro came in at $3.84 billion, compared with estimates of $3.80 billion- LSEG
** Up to last close, LLY was up 16.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。